These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28000076)

  • 1. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
    Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.
    Murphy BL; L Hoskin T; Heins CDN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 Sep; 24(9):2518-2525. PubMed ID: 28484921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.
    Killelea BK; Yang VQ; Mougalian S; Horowitz NR; Pusztai L; Chagpar AB; Lannin DR
    J Am Coll Surg; 2015 Jun; 220(6):1063-9. PubMed ID: 25868410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Shifting Paradigm for Breast Cancer Surgery in Patients Undergoing Neoadjuvant Chemotherapy.
    Kantor O; Ajmani G; Wang CH; Datta A; Yao K
    Ann Surg Oncol; 2018 Jan; 25(1):164-172. PubMed ID: 29127538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
    Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
    J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
    Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
    Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
    Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
    Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
    Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
    Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.
    Spronk PER; van Bommel ACM; Siesling S; Wouters MWJM; Vrancken Peeters MTFD; Smorenburg CH
    Breast; 2017 Dec; 36():34-38. PubMed ID: 28942098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
    Xian Z; Quinones AK; Tozbikian G; Zynger DL
    Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
    Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.